![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Announces Closing of Its Previously Announced Private Placement of Unregistered Convertible Notes and Warrants
July 01, 2011 16:05 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., July 1, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it closed its previously announced private placement of...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Announces $4.6 Million Private Placement of Unregistered Convertible Note and Warrants
June 22, 2011 12:10 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 22, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that it has entered into an agreement for the issuance and...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials With Oxycyte(R) PFC for Traumatic Brain Injury Into India
June 07, 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., June 7, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received approval by the Drug Controller General of...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics' Chairman and CEO Chris Stern Announces Retirement of President and COO Richard Kiral
March 31, 2011 17:30 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 31, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced the Board of Directors accepted the resignation of President...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Reports Financial Results for Third Quarter FY2011
March 21, 2011 18:03 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 21, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Announces Third Quarter FY2011 Financial Results Conference Call and Webcast
March 14, 2011 18:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 14, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the Company plans to report third quarter fiscal year...
![Oxygen Biotherapeutics, Inc. Logo](http://www.globenewswire.com/en/Attachment/LogoDisplay/218847?filename=218847.jpg&size=2)
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Mexican Sales and Distribution Company
March 10, 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 10, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has entered into an agreement with independently owned and...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Receives U.S. Army Grant for Studies of Oxycyte(R), a Novel Traumatic Brain Injury Therapeutic for Combat Casualties
March 02, 2011 02:00 ET
|
Oxygen Biotherapeutics, Inc.
MORRISVILLE, N.C., March 2, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received a $2.075 million, two-year grant from the U.S....
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte(TM) Gel
January 28, 2011 00:30 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SWX:OXBT) today announced it has signed a research contract with Hackensack University Medical Center (HUMC)...
![Oxygen Biotherapeutics, Inc. Logo](/news-release/logo/218847/0/218847.jpg?lastModified=12%2F09%2F2016%2023%3A28%3A07&size=2)
Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Swiss Sales and Distribution Company
January 12, 2011 11:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C. and ZURICH, Switzerland, Jan. 12, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced it has entered into an agreement with the newly formed,...